Objective:To study the effect of intrapleural endostatin and mannatide infusion on malignant molecule expression in pleural fluid of malignant pleural effusion.Methods:Patients with lung cancer and malignant pleural e...Objective:To study the effect of intrapleural endostatin and mannatide infusion on malignant molecule expression in pleural fluid of malignant pleural effusion.Methods:Patients with lung cancer and malignant pleural effusion treated in our hospital between April 2013 and December 2015 were selected and randomly divided into two groups, the observation group received intrapleural endostatin and mannatide infusion treatment and control group accepted routine intrapleural infusion treatment. 4 weeks after treatment, the pleural fluid samples were collected to determine the levels of tumor markers, invasion-related molecules, VEGF-related molecules and anti-tumor cytokines.Results:4 weeks after treatment, CEA, CYFRA21-1, NSE, SCC-Ag, CXCL12, CXCR4, MMP2, MMP9, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2 and VEGF-R3 levels in pleural fluid of observation group were significantly lower than those of control group while LASS2/TMSG-1, IFN-γ, IL-2, TNF-α, IL-17 and IL-23 levels were significantly higher than those of control group.Conclusion:Intrapleural endostatin and mannatide infusion treatment of malignant pleural effusion can more effectively kill cancer cells, inhibit cell invasion, angiogenesis and lymphangiogenesis, and enhance antitumor immune response.展开更多
In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions report...In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed.Moreover,independent high-risk factors for severe infusion reactions were assessed by the Chi-square test.The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old(71.05%)and primarily occurred within 10 min of drug administration(86.84%),and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide.Therefore,the patients with advanced age,previous history of drug allergy,basic medical history,and the first use of this drug,especially within 10 min after administration,should be highly vigilant and closely monitored.展开更多
文摘Objective:To study the effect of intrapleural endostatin and mannatide infusion on malignant molecule expression in pleural fluid of malignant pleural effusion.Methods:Patients with lung cancer and malignant pleural effusion treated in our hospital between April 2013 and December 2015 were selected and randomly divided into two groups, the observation group received intrapleural endostatin and mannatide infusion treatment and control group accepted routine intrapleural infusion treatment. 4 weeks after treatment, the pleural fluid samples were collected to determine the levels of tumor markers, invasion-related molecules, VEGF-related molecules and anti-tumor cytokines.Results:4 weeks after treatment, CEA, CYFRA21-1, NSE, SCC-Ag, CXCL12, CXCR4, MMP2, MMP9, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2 and VEGF-R3 levels in pleural fluid of observation group were significantly lower than those of control group while LASS2/TMSG-1, IFN-γ, IL-2, TNF-α, IL-17 and IL-23 levels were significantly higher than those of control group.Conclusion:Intrapleural endostatin and mannatide infusion treatment of malignant pleural effusion can more effectively kill cancer cells, inhibit cell invasion, angiogenesis and lymphangiogenesis, and enhance antitumor immune response.
基金Guangzhou Municipal Science and Technology Bureau(Grant No.202102010186 and 202102010313).
文摘In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed.Moreover,independent high-risk factors for severe infusion reactions were assessed by the Chi-square test.The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old(71.05%)and primarily occurred within 10 min of drug administration(86.84%),and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide.Therefore,the patients with advanced age,previous history of drug allergy,basic medical history,and the first use of this drug,especially within 10 min after administration,should be highly vigilant and closely monitored.
